Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WT1 DNA fusion gene vaccination in hematological malignancies
2009-017340-14Phase 2Terminated
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Jun 2010
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of p.DOM-WT1-37 and p.DOM-WT1-126 in chronic myelogenous leukemia (CML) and acute myeloid leukemia (AML) (2 arms), sponsored by University Hospital Southampton NHS Foundation Trust. Primary endpoint: Intention-to-treat analysis of vaccine effects. Started Jun 2010; status: terminated.
02
Drugs
p.DOM-WT1-37p.DOM-WT1-126
03
Conditions
chronic myelogenous leukemia (CML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2009-017340-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017340-14.